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 25 
ABSTRACT  26 
The progression of mycobacterial diseases requires the development of new therapeutics. Here, 27 
we evaluated the efficacy and selectivity of a panel of Cyclophostin and Cyclipostins analogs 28 
(CyCs) against various bacteria and mycobacteria. The activity of these 26 CyCs was first 29 
assayed using the agar plate method. Compounds exhibiting a 50-100% growth inhibition rate 30 
were then selected to determine their MIC using the REMA assay. The best drug candidate was 31 
further tested against mycobacterial clinical isolates and bacteria responsible for nosocomial 32 
infections. These included 6 Gram-negative, 5 Gram-positive bacteria, 29 rapid-growing 33 
mycobacteria belonging to the M. chelonae-abscessus clade and 3 slow-growing mycobacteria 34 
(Mycobacterium marinum, Mycobacterium bovis BCG, Mycobacterium tuberculosis). Among 35 
the 26 CyCs tested, 10 were active and their inhibitory activity was exclusively restricted to 36 
mycobacteria. The best candidate, CyC17, further tested on the 26 clinical strains showed a high 37 
selectivity for mycobacteria with MIC values (<2 up to 40 µg/mL) comparable to those of most 38 
classical antibiotics used to treat M. abscessus infections. Together, these results support the 39 
fact that such CyCs represent a new family of potent and selective inhibitors against 40 
mycobacteria. This is of particular interest for future chemotherapeutic developments against 41 
mycobacterial-associated infections, especially against M. abscessus the most drug-resistant 42 
mycobacterial species. 43 
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1. Introduction 49 
The Mycobacterium genus comprises more than 200 species classified mainly on their 50 
pathogenicity and growth rates. Mycobacteria can be separated into rapidly-growing 51 
mycobacteria (RGM) that include saprophytic species and opportunistic species such as the M. 52 
abscessus complex, M. chelonae and M. fortuitum; and slow-growing mycobacteria (SGM) 53 
comprising strict and opportunistic pathogens, such as the M. tuberculosis complex and the M. 54 
avium complex, respectively [1]. Treatment of mycobacterial infections remains challenging, 55 
essentially because of the presence of a complex lipid-rich cell wall [2], whose general 56 
composition and architecture is shared by both RGM and SGM and which contributes to its low 57 
permeability to many antibiotics, thus limiting the therapeutic options. In addition, the treatment 58 
duration is long, ranging from 6 to 9 months for tuberculosis and for up to 2 years for several 59 
mycobacterial lung infections due to atypical mycobacteria, such as M. kansasii or M. 60 
abscessus. The emergence of multi-drug resistant mycobacteria such as M. abscessus, or M. 61 
tuberculosis isolates (responsible for MDR-TB) strongly impacts the treatment success rates 62 
with an increased incidence of treatment failure and death [3]. Another major issue relates to 63 
the emergence of RGM-caused infections [4]. Among them, the difficult-to-manage M. 64 
abscessus complex represents one of the most drug-resistant for which standardized 65 
chemotherapeutic regimens are still lacking [5]. Therefore, more efficient anti-mycobacterial 66 
agents are needed.  67 
Previously, we evaluated analogues of natural Cyclophostin and Cyclipostins (CyCs) for 68 
their activity against M. tuberculosis and demonstrated that they efficiently inhibited M. 69 
tuberculosis growing either extracellularly or within macrophages [6]. Of major importance, 70 
no cytotoxicity towards the host mammalian cells has been observed for these CyC compounds 71 
at concentrations up to 100 µM (Table 2) [6]. Using competitive labelling/enrichment assays 72 
and mass spectrometry, 23 putative CyC targets were identified, all belonging to the 73 
4 
serine/cysteine hydrolase family proteins known to play a role in the lifecycle and/or 74 
pathogenesis of M. tuberculosis [7].  75 
Herein, we examined the selectivity and activity of a set of 26 CyC analogs (Figure S1) 76 
against a variety of Gram-positive and Gram-negative bacteria. We also included a large panel 77 
of mycobacterial clinical isolates. Our results strongly support the potent and specific activity 78 
of CyCs against mycobacteria. These molecules constitute an unexploited chemical class of 79 
active compounds with promising translational development possibilities for the treatment of 80 
mycobacterial infections. 81 
 82 
2. Materials and Methods 83 
2.1. Synthesis of Cyclipostins and Cyclophostin (CyC) analogs.  84 
The 26 CyC analogs were previously synthesized and obtained at 98% purity as reported 85 
in [8-10]. Stock solutions (4 mg/mL) of each CyC were prepared in dimethyl sulfoxide 86 
(DMSO) prior to susceptibility testing.  87 
2.2. Bacterial strains and growth condition.  88 
Six Gram-negative, 5 Gram-positive bacteria, 29 RGM (mainly clinical isolates) and 3 89 
SGM were included in this study (Table 1). The clinical isolates were collected during the 90 
epidemiological study performed in 2004 [11] and include representatives of the M. chelonae-91 
abscessus clade (10 M. abscessus, 4 M. massiliense, 2 M. bolletii, and 10 M. chelonae strains) 92 
obtained from either cystic fibrosis patients (CF isolates) or non-cystic fibrosis patients (non-93 
CF isolates). M. smegmatis mc2155 strain was routinely grown in Middlebrook 7H9 broth (BD 94 
Difco) supplemented with 0.2% glycerol, 0.05% Tween 80 (Sigma-Aldrich) (7H9-S). M. 95 
marinum ATCC BAA-535/M, M. bovis BCG Pasteur, M. abscessus CIP104536T with either a 96 
smooth (S) or rough (R) morphotype, and M. tuberculosis mc26230 (H37Rv RD1 panCD 97 
[12]) strains were grown in this 7H9-S medium supplemented with 10% oleic acid, albumin, 98 
5 
dextrose, catalase (OADC enrichment; BD Difco) (7H9-SOADC). In the case of M. tuberculosis 99 
mc26230, 24 µg/mL D-panthothenate (Sigma-Aldrich) was also added in the 7H9-SOADC 100 
medium. All cultures were kept at 37°C without shaking, except M. marinum which was grown 101 
at 32°C. The 5 Gram-positive strains (i.e., Staphylococcus aureus, Enterococcus faecalis, 102 
Streptococcus pneumoniae, Staphylococcus epidermidis, Enterococcus faecium) and the 6 103 
Gram-negative strains (i.e., Escherichia coli, Pseudomonas aeruginosa, Enterobacter 104 
aerogenes, Serratia marcescens, Stenotrophomonas maltophilia, Burkholderia cepacia 105 
complex) were grown at 37°C in LB Broth Base medium (ThermoFisher Scientific).  106 
2.3. Drug susceptibility testing on solid medium.  107 
This was performed in 24-well suspension culture plates (Greiner bio-one) as described 108 
in [13]. E. coli and P. aeruginosa were grown on LB agar medium at 37°C. All mycobacteria 109 
were grown at either 32°C (M. marinum) or 37°C (M. smegmatis, M. bovis BCG, M. abscessus 110 
S and R variants, and M. tuberculosis mc26230) on Middlebrook 7H10 agar (BD Difco) 111 
supplemented with 10% OADC and 24 µg/mL D-panthothenate (M. tuberculosis mc26230). 112 
The wells were filled with 1 mL of the appropriate medium containing each of the CyC analogs 113 
at a single 30 µM final concentration. Each screening plate contained negative (DMSO) and 114 
positive (50 μM antibiotics) controls, as well as one well for sterility control (i.e., medium 115 
alone). For the 100% inhibition control we used 50 µM kanamycin (Sigma Aldrich) for M. 116 
marinum, M. abscessus, M. smegmatis, M. bovis BCG, M. tuberculosis and E. coli; and 50 µM 117 
carbenicillin (Sigma Aldrich) for P. aeruginosa. Each well was spotted with 10 µL of a bacterial 118 
culture at 5 × 105 cells/mL. Incubation time varied from 1 day to 2 weeks depending on the 119 
strain tested. The CyC compounds leading to a minimum of 50% growth inhibition were 120 
selected for subsequent minimal inhibitory concentrations (MIC) determination using the 121 
REMA assay. 122 
2.4. Resazurin microtiter assay (REMA) for MIC determination.  123 
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Susceptibility testing was performed using the Middlebrook 7H9 broth microdilution 124 
method. All assays for each strain were carried out at least in triplicate. MICs of the CyCs, 125 
selected from solid medium screening against the various bacterial strains, were determined in 126 
96-well flat-bottom Nunclon Delta Surface microplates with lid (ThermoFisher Scientific, ref. 127 
167008) using the resazurin microtiter assay (REMA [14, 15]). Briefly, log-phase bacteria were 128 
diluted to a cell density of 5 × 106 cells/mL in 7H9-SOADC (7H9 broth + 10% OADC + 0.2% 129 
glycerol + 0.05% Tween 80, and 24 µg/mL D-panthothenate when needed). Then 100 µL of 130 
the above inoculum (i.e., 5 × 105 cells per well) was added to each well containing 100 µL 7H9-131 
SOADC medium, serial two-fold dilutions of the selected CyC analog or controls to a final 132 
volume of 200 µL. Growth controls containing no inhibitor (i.e., bacteria only = B), inhibition 133 
controls containing 50 µg/mL kanamycin and sterility controls (i.e., medium only = M) without 134 
inoculation were also included. Plates were incubated at 37°C (32°C for M. marinum) in a 135 
humidity chamber [16] to prevent evaporation for either 3-5 days (M. smegmatis, M. abscessus) 136 
or 10-14 days (M. marinum, M. bovis BCG, M. tuberculosis mc26230). Then, 20 µL of a 0.025% 137 
(w/v) resazurin solution was added to each well, and the plates were incubated at 37°C for color 138 
change from blue to pink or violet and for a reading of fluorescence units (FU). Fluorescence 139 
corresponding to the resazurin reduction to its metabolite resorufin was quantified using a 140 
Tecan Spark 10M multimode microplate reader (Tecan Group Ltd, France) with excitation at 141 
530 nm and emission at 590 nm. For fluorometric MIC determinations, a background 142 
subtraction was performed on all wells with a mean of M wells. Relative fluorescence units 143 
were defined as: RFU% = (test well FU/mean FU of B wells) × 100. MIC values were 144 
determined by fitting the RFU% sigmoidal dose-response curves [15] in Kaleidagraph 4.2 145 
software (Synergy Software). The lowest drug concentrations inhibiting 90% of growth were 146 
defined as the MIC90. Isoniazid (INH), amikacin (AMK), imipenem (IPM) and cefoxitin (FOX) 147 
were used as reference drugs.   148 
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3. Results and Discussion 149 
3.1. Screen of CyCs susceptibility testing on solid medium 150 
To explore the efficacy and the antibacterial spectrum of the CyC analogues, a 151 
preliminary screen on solid medium was first performed with the each of the 26 CyCs at a fixed 152 
30 µM final concentration using a selected panel consisting of 6 mycobacterial species (i.e., M. 153 
smegmatis, M. marinum, M. abscessus R and S, M. bovis BCG and M. tuberculosis mc26230) 154 
and 2 Gram-negative bacteria (i.e., Escherichia coli and Pseudomonas aeruginosa). After a 155 
period of incubation (from 1 day to 2 weeks), 10 out of the 26 CyCs were found to inhibit 156 
growth in the range of 50-100% relative to the positive growth control (i.e., bacteria without 157 
antibiotics). Remarkably, this effect was restricted to mycobacteria only (see Table S1), while 158 
under the same conditions, the growth of E. coli and P. aeruginosa was not impacted.  159 
 160 
3.2. MIC determination 161 
The potency of the selected CyC7(,), CyC8(,), CyC9(), CyC10(), CyC11, CyC17 and 162 
CyC17(,) was next confirmed by determining their MICs towards each respective 163 
mycobacterial strain, using the REMA assay [14, 15] (Table 2). Nearly all selected CyCs were 164 
active against M. marinum and M. bovis BCG growth with moderate (4.2-25.9 µg/mL) to good 165 
(0.6-2.2 µg/mL) MIC90. Moreover, the obtained MICs against M. tuberculosis mc
26230 were 166 
consistent with those recently reported against M. tuberculosis H37Rv extracellular growth [6]. 167 
Among the 10 CyCs tested, only CyC18( and CyC17 inhibited the growth of all mycobacteria 168 
investigated with MICs ranging from 0.18 to 11.2 µg/mL (Table 2). Of importance, CyC17 was 169 
also highly active against both R and S variants of M. abscessus with a lower MIC (0.18 µg/mL 170 
and 6.4 µg/mL against M. abscessus R and S, respectively) than AMK, IMP and FOX used as 171 
reference drugs (Table 2) as well as most conventional antibiotics used in clinical settings [17].  172 
 173 
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3.3. Potency and selectivity of the best CyC17 inhibitor against clinical isolates. 174 
The CyC17 efficiency/selectivity was investigated deeper by testing its activity towards 175 
26 clinical isolates belonging to the M. chelonae-abscessus clade and several Gram-negative 176 
and Gram-positive bacterial species (Table 3). As anticipated, CyC17 was only active against 177 
M. abscessus and M. chelonae isolates (Table 3). Of interest, MIC50 values for M. abscessus 178 
and M. chelonae (10 and 40 µg/mL, respectively) were comparable to those of amikacin (12.5 179 
µg/mL) [18], cefoxitin (32 µg/mL) or imipenem (16 µg/mL) [19]. M. abscessus complex 180 
isolates were also more sensitive than M. chelonae isolates, with M. bolletii appearing as the 181 
most susceptible organism (Table 3).  182 
Overall, these results confirm the potential of CyCs as promising anti-mycobacterial 183 
candidates. This selective activity against mycobacteria might be related to the cell envelope 184 
composition [2] which is unique, and/or to the increased ability of these hydrophobic 185 
compounds to cross this lipid-rich cell wall barrier. This hypothesis is relevant with the recent 186 
identification of potential targets for CyC17 which are mostly involved in M. tuberculosis lipid 187 
metabolism and/or in cell wall biosynthesis, such as the Antigen 85 complex playing key role 188 
in mycolic acid metabolism, which is restricted to mycobacteria [6].  189 
 190 
4. Conclusion 191 
Taking into account all these results, we thus propose the CyCs analogs to be considered 192 
as selective inhibitors of mycobacteria and attractive candidates to be further exploited in the 193 
fight against mycobacterial-related diseases. Additionally, CyC17 was found to be active against 194 
the multi-resistant species of the M. abscessus complex. Further work to decipher the 195 
physiological target(s) of CyC17 and to elucidate its mode of action in M. abscessus is currently 196 
in progress. 197 
 198 
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Table 1.  279 
Bacterial strains used in the study. 280 
Species Bacterial strains Source 
Gram negative bacteria   
Escherichia coli DH10B Reference strain  
Escherichia coli Clinical isolate [11] 
Pseudomonas aeruginosa PA01 Reference strain  
Pseudomonas aeruginosa Clinical isolate [11] 
Enterobacter aerogenes Clinical isolate [11] 
Serratia marcescens Clinical isolate [11] 
Stenotrophomonas maltophilia Clinical isolate [11] 
Burkholderia cepacia complex Clinical isolate [11] 
Gram positive bacteria   
Staphylococcus aureus Clinical isolate [11] 
Enterococcus faecalis Clinical isolate [11] 
Streptococcus pneumoniae Clinical isolate [11] 
Staphylococcus epidermidis Clinical isolate [11] 
Enterococcus faecium Clinical isolate [11] 
Mycobacteria   
M. bovis BCG Pasteur Reference strain  
M. tuberculosis mc26230 Reference strain [12] 
M. marinum M Reference strain  
M. smegmatis mc2155 Reference strain  
M. abscessus CIP 104536T Reference strain  
M. abscessus (RPC95) CF isolate [11] 
M. abscessus (RPC96) CF isolate [11] 
M. abscessus (RPC98) CF isolate [11] 
M. abscessus (RPC101) CF isolate [11] 
M. abscessus (RPC102) CF isolate [11] 
M. abscessus (RPC104) CF isolate [11] 
M. abscessus (RPC105) CF isolate [11] 
M. abscessus (RPC106) CF isolate [11] 
M. abscessus (RPC109) CF isolate [11] 
M. abscessus (RPC110) CF isolate [11] 
M. massiliense (RPC99) CF isolate [11] 
M. massiliense (RPC100) CF isolate [11] 
M. massiliense (RPC107) CF isolate [11] 
M. massiliense (RPC103) CF isolate [11] 
M. bolletii (RPC97) CF isolate [11] 
M. bolletii (RPC108) CF isolate [11] 
M. chelonae (RPC128) CF isolate [11] 
M. chelonae (RPC129) CF isolate [11] 
M. chelonae (RPC130) CF isolate [11] 
M. chelonae (RPC131) Non-CF isolate [11] 
M. chelonae (RPC132) Non-CF isolate [11] 
M. chelonae (RPC057) Non-CF isolate [11] 
14 
M. chelonae (RPC059) Non-CF isolate [11] 
M. chelonae (RPC061) Non-CF isolate [11] 
M. chelonae (RPC063) Non-CF isolate [11] 
M. chelonae (RPC066) Non-CF isolate [11] 
 281 
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 283 
Table 2.  284 
Antibacterial activities of the selected active CyC compounds as compared to four standard 285 
antimicrobial agents against a first panel of mycobacterial strains 286 
 287 
Compounds 
MIC90 (µg/mL) 
a 
CC50 
b 
(µg/mL) M. smegmatis 
mc2155 
M. abscessus  
CIP 104536T M. marinum M. bovis BCG 
M. tuberculosis 
mc26230 
Smooth Rough 
CyC7(α)    11.8 25.9  >40 
CyC7(β)    2.2 17.7 13.9 >40 
CyC8(α)    0.63 8.5 18.6 >40 
CyC8(β)    4.2 9.3  >10 
CyC9(β)    7.8 26.2  >45 
CyC10(α)    11.4   >50 
CyC11    9.0   >45 
CyC17 0.81 6.4 0.18 0.74 0.58 1.2 >45 
CyC18(α)    7.8 9.6 19.4 >45 
CyC18(β) 6.7 6.0 4.9 11.2 11.5 2.6 >45 
INH 5.6   9.3 0.10 0.15 >20 
AMK  4.7 7.9 1.7 0.48 0.63  
IPM  1.9 8.9     
FOX  4.0 12.0     
a MIC90 corresponding to the concentration leading to 90% growth inhibition as determined by the 288 
REMA assay, are expressed as mean values of two independent assays performed in triplicate 289 
(CV% < 5%). b CC50: compound concentration leading to 50% cell toxicity, determined on murine 290 
(raw264.7) macrophages – data from [6]. INH: isoniazid; AMK: amikacin; IPM: imipenem; FOX: 291 
cefoxitin. 292 
 293 
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Table 3.  296 
MICs (in µg/mL) of CyC17 on a panel of M. abscessus and M. chelonae clinical strains isolated 297 
from cystic fibrosis and non-cystic fibrosis patients a 298 
 299 
Clinical isolates N° of strains with indicated MIC   
(number of strains) < 2 5 10 20 40 80 MIC50 MIC90 
Mycobacteria         
All (26) 2 2 8 5 4 5 10 80 
M. abscessus (10) 1 2 3 3 1  10 40 
M. massiliense (4)   2  2  10 10 
M. bolletii (2) 1  1    <2 10 
M. chelonae (10)   2 2 1 5 40 80 
         
Gram-negative bacteria         
Escherichia coli       >820  
Pseudomonas aeruginosa       >820  
Serratia marcescens       >820  
Stenotrophomonas maltophilia       >820  
Burkholderia cepacia complex       >820  
         
Gram-positive bacteria         
Staphylococcus aureus       >820  
Staphylococcus epidermidis       >820  
Streptococcus pneumoniae       >820  
Enterobacter aerogenes       >820  
Enterococcus faecalis       >820  
Enterococcus faecium       >820  
a
 MICs are expressed as mean values of triplicate. Respective MIC50 / MIC90 values of standard 300 
antimicrobial agents against the M. chelonae – M. abscessus clinical isolates: imipenem 16 / 32 µg/mL 301 
and cefoxitin 32 / 64 µg/mL [19]. 302 
 303 
